The cost effectiveness of adalimumab (HUMIRA®) in patients with RA:: A Finnish analysis

被引：0
|
作者：
Bansback, NJ
Brennan, A
Sengupta, N
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：513 / 514
页数：2
相关论文
共 50 条
  • [1] The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA
    Bansback, NJ
    Brennan, A
    Sengupta, N
    Pang, F
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 512 - 513
  • [2] The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Winding, B.
    Cifaldi, M.
    Pang, F.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 15 - 15
  • [3] Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)
    Bansback, N
    Brennan, A
    Sengupta, N
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [4] Cost effectiveness of adalimumab (HUMIRA™, Abbott) in the treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Bansback, NJ
    Brennan, A
    Sengupta, N
    Chang, KY
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S215 - S215
  • [5] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    [J]. RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [6] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Pang, F.
    Winding, B.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
  • [7] The cost-effectiveness of adalimumab (HUMIRA™, Abbott) in patients with rheumatoid arthritis:: A Swedish analysis.
    Bansback, NJ
    Brennan, A
    Ghatnekar, O
    Sengupta, N
    Chang, KY
    Hansen, M
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S611 - S611
  • [8] The cost utility of adalimumab (HUMIRA®) and infliximab (REMICADE) in the treatment of patients with early rheumatoid arthritis (RA):: US analysis
    Davies, AS
    Hutton, J
    Cifaldi, MA
    Pang, F
    Spencer-Green, G
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 393 - 393
  • [9] Workplace impacts of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA)
    Birnbaum, Howard
    Pike, Crystal
    Kaufman, Rebecca
    Schiller, Matthew
    Shi, Lizheng
    Sun, Peter
    Ray, Saurabh
    Cifaldi, Mary
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S459 - S459
  • [10] Subgroup analysis of radiographic progression in RA patients with moderate disease treated with adalimumab (Humira®)
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Spencer-Green, GT
    Szczerbak, NA
    Mydler, TT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 267 - 267
12345